Deploying bacteriophage combinatorial therapy to eradicate resistant Klebsiella pneumoniae UTIs: innovative and...

Area of Science:

• Microbiology
• Infectious Diseases
• Therapeutics

Background:

• Klebsiella pneumoniae is a WHO priority pathogen, frequently causing untreatable multidrug-resistant (MDR) and carbapenem-resistant (CRKP) urinary tract infections (UTIs).
• The rise of antibiotic resistance has created a therapeutic impasse, necessitating novel treatment strategies.

Purpose of the Study:

• To critically evaluate the potential of bacteriophage (phage) therapy for MDR K. pneumoniae UTIs.
• To summarize the biological rationale, translational landscape, and clinical challenges of phage therapy for these infections.

Main Methods:

• Review of existing literature on phage therapy mechanisms, including bacterial lysis and biofilm disruption.
• Analysis of preclinical, compassionate-use, and early clinical trial data for phage therapy in K. pneumoniae UTIs.
• Identification of key issues and strategic frameworks for clinical deployment.

Main Results:

• Phage therapy offers a precision approach to selectively target and eliminate K. pneumoniae.
• Promising preclinical and compassionate-use data exist, but controlled clinical trial outcomes are limited.
• Strategic frameworks, including phage-antibiotic synergy (PAS) and personalized approaches, are crucial for effective clinical use.

Conclusions:

• Bacteriophage therapy holds significant potential as an alternative or adjunct treatment for MDR K. pneumoniae UTIs.
• Addressing challenges in phage cocktail design, clinical trial design, and regulatory pathways is essential for successful integration.
• Further research is required to establish robust clinical evidence and optimize phage therapy protocols.